NASDAQ:ATHA Athira Pharma (ATHA) Stock Price, News & Analysis $10.33 +0.26 (+2.58%) As of 05/22/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Athira Pharma Stock (NASDAQ:ATHA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Athira Pharma alerts:Sign Up Key Stats Today's Range$10.27▼$11.4450-Day Range$6.91▼$11.6852-Week Range$0.23▼$8.36Volume22,984 shsAverage Volume602,475 shsMarket Capitalization$40.74 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingSell Company Overview Athira Pharma, Inc. is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS). The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system. Fosgonimeton has advanced through Phase 1 and Phase 2 clinical trials, where it has been evaluated for safety, tolerability and preliminary efficacy in patients with mild to moderate Alzheimer’s disease and other forms of cognitive impairment. In addition to ATH‐1017, the company is exploring follow‐on small‐molecule candidates designed to target related pathways and broaden the potential therapeutic impact across multiple neurodegenerative indications. Athira Pharma went public in 2019 and is traded on the Nasdaq under the symbol ATHA. The company conducts clinical studies in the United States and Europe in collaboration with academic research centers and contract research organizations. Leadership has included key figures from both the biotech and neuroscience research communities, with a management team experienced in drug development, clinical operations and regulatory affairs. Athira continues to engage with strategic partners to support its mission of bringing novel, disease‐modifying treatments to patients suffering from progressive neurological disorders.AI Generated. May Contain Errors. Read More Athira Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreATHA MarketRank™: Athira Pharma scored higher than 14% of companies evaluated by MarketBeat, and ranked 815th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingAthira Pharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Downside RiskAthira Pharma has a consensus price target of $4.00, representing about 60.3% downside from its current price of $10.07.Amount of Analyst CoverageAthira Pharma has received no research coverage in the past 90 days.Read more about Athira Pharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Athira Pharma are expected to grow in the coming year, from ($2.35) to ($0.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Athira Pharma is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Athira Pharma is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAthira Pharma has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ATHA. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAthira Pharma does not currently pay a dividend.Dividend GrowthAthira Pharma does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentAthira Pharma has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Athira Pharma this week, compared to 0 articles on an average week. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Athira Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders19.80% of the stock of Athira Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions57.12% of the stock of Athira Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Athira Pharma's insider trading history. Receive ATHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Athira Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATHA Stock News HeadlinesAthira Pharma (NASDAQ:ATHA) Trading Down 4.7% - What's Next?May 22 at 2:27 AM | americanbankingnews.comATHA Energy Announces $25 Million LIFE Private Placement of Flow-Through SharesJanuary 15, 2026 | globenewswire.com$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…May 23 at 1:00 AM | Paradigm Press (Ad)Athira Pharma changes name, ticker symbolJanuary 9, 2026 | msn.comAthira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA”January 9, 2026 | markets.businessinsider.comWhy Is Athira Pharma Stock Spiking After Breast Cancer Asset Acquisition?December 18, 2025 | benzinga.comAthira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer TranscriptDecember 18, 2025 | seekingalpha.comAthira Pharma stock soars after acquiring rights to Phase 3 breast cancer drugDecember 18, 2025 | za.investing.comSee More Headlines ATHA Stock Analysis - Frequently Asked Questions How have ATHA shares performed this year? Athira Pharma's stock was trading at $7.57 on January 1st, 2026. Since then, ATHA stock has increased by 33.0% and is now trading at $10.07. How were Athira Pharma's earnings last quarter? Athira Pharma, Inc. (NASDAQ:ATHA) issued its earnings results on Thursday, November, 6th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $1.51. When did Athira Pharma's stock split? Athira Pharma's stock reverse split on Thursday, September 18th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 17th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Athira Pharma IPO? Athira Pharma (ATHA) raised $192 million in an IPO on Friday, September 18th 2020. The company issued 12,000,000 shares at $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel acted as the underwriters for the IPO and JMP Securities was co-manager. How do I buy shares of Athira Pharma? Shares of ATHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Athira Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Athira Pharma investors own include Pfizer (PFE), PayPal (PYPL), Advanced Micro Devices (AMD), Alibaba Group (BABA), Intel (INTC) and Meta Platforms (META). Company Calendar Last Earnings11/06/2025Today5/23/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATHA CIK1620463 Webathira.com Phone425-620-8501FaxN/AEmployees40Year Founded2011Price Target and Rating Average Price Target for Athira Pharma$4.00 High Price Target$4.00 Low Price Target$4.00 Potential Upside/Downside-61.3%Consensus RatingSell Rating Score (0-4)1.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($9.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$96.94 million Net MarginsN/A Pretax MarginN/A Return on Equity-107.06% Return on Assets-89.89% Debt Debt-to-Equity RatioN/A Current Ratio9.70 Quick Ratio9.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.60 per share Price / Book0.89Miscellaneous Outstanding Shares3,944,000Free Float3,163,000Market Cap$40.74 million OptionableNo Data Beta2.79 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:ATHA) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athira Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
